Results 151 to 160 of about 178,801 (195)

Self and parasite-derived peptides selected upon DERAA-bearing HLA-DRB1 alleles activate CD4+ T cells from Chagas cardiomyopathy patients and are associated with ventricular dysfunction. [PDF]

Front Immunol
Souza-Silva TG, Neves EGA, Teixeira-Carvalho A, Figueiredo AB, Morais KLP, Apostólico J, Rodrigues H, Kalil J, Juliano MA, Juliano L, Araújo SS, Pantaleao AN, Mutarelli A, Nunes MCP, Gollob KJ, Dutra WO.   +15 more
europepmc   +1 more source

Unraveling the role of miRNAs as biomarkers in Chagas cardiomyopathy: Insights into molecular pathophysiology. [PDF]

PLoS Negl Trop Dis
Ribeiro HG, Galdino OA, de Souza KSC, Rosa Neta AP, Lin-Wang HT, Cunha-Neto E, Rezende AA, Silbiger VN.   +7 more
europepmc   +1 more source

Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial.

JAMA Cardiol
Martinelli-Filho M, Marin-Neto JA, Scanavacca MI, de Paola AAV, Medeiros PTJ, Owen R, Pocock SJ, de Siqueira SF, CHAGASICS investigators.   +8 more
europepmc   +1 more source

Adipocyte-released adipomes in Chagas cardiomyopathy: Impact on cardiac metabolic and immune regulation. [PDF]

iScience
Thangavel H, Dhanyalayam D, Kim M, Lizardo K, Sidrat T, Lopez JG, Wang X, Bansal S, Nagajyothi JF.   +8 more
europepmc   +1 more source

Factors influencing the use of direct oral anticoagulants among patients with chronic chagas cardiomyopathy. [PDF]

Arch Peru Cardiol Cir Cardiovasc
Gómez-Ochoa SA, Rojas LZ, Alarcón Meléndez LJ, Quintero Santana MA, Becerra-Motta LP, Serrano-García AY, Echeverría LE.   +6 more
europepmc   +1 more source

Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy [PDF]

New England Journal of Medicine, 2015
The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven.We conducted a prospective, multicenter, randomized study involving 2854 patients with Chagas' cardiomyopathy who received benznidazole or placebo for up to 80 days and were followed for a mean of 5.4 years. The primary outcome in the time-to-event analysis
Felipe Guhl, Antonio Mattos, Sérgio Sosa-Estani   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Chagas Disease: Chronic Chagas Cardiomyopathy

Current Problems in Cardiology, 2021
Chagas disease (CD) is a tropical vector-borne infection caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), also known as American Trypanosomiasis. It is considered endemic in all South and Central America and in this past decades its becoming a burden particularly in the United States and Europe due to human migration. The vast majority of
Natalia Giraldo Echavarría, Luis E. Echeverría, Merrill Stewart, Catalina Gallego, Clara Saldarriaga   +4 more
openaire   +2 more sources

Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic Trypanosoma cruzi–Seropositive Former Blood Donors [PDF]

Circulation, 2013
BackgroundVery few studies have measured disease penetrance and prognostic factors of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-infected persons.Methods and resultsWe performed a retrospective cohort study among initially healthy blood ...
Claudia D L Oliveira, Vandana Sachdev, Michael Busch   +2 more
exaly   +2 more sources

Autoantibodies in Chagas' Cardiomyopathy and Arrhythmias

Autoimmunity, 2001
Pablo A Chiale, P A Chiale
exaly   +3 more sources

Chagas cardiomyopathy and captopril

European Heart Journal, 1992
Chagas disease is a leading cause of heart failure in Latin America. Sudden death occurs in approximately 40% of patients with heart failure due to Chagas disease. We report a single blind, cross-over trial of prolonged treatment with captopril and placebo in 18 Chagas disease patients with class IV NYHA heart failure.
Roberti, Roberto Rinaldo UNIFESP, Martinez, E. E., Andrade, José Lazaro de UNIFESP, Araujo, V. L., Brito, Flavio Souza UNIFESP, Portugal, Oscar Pimentel UNIFESP, Horowitz, S. F.   +6 more
openaire   +3 more sources